Literature DB >> 20305136

Myocardial infarction is a complication of factor H-associated atypical HUS.

Marion Sallée1, Laurent Daniel, Marie-Dominique Piercecchi, Dominique Jaubert, Veronique Fremeaux-Bacchi, Yvon Berland, Stephane Burtey.   

Abstract

Cardiac complications are frequently seen in thrombotic thrombocytopaenic purpura related to ADAMTS13 deficiency. We describe the case of a 43-year-old woman who was diagnosed with an atypical haemolytic-uraemic syndrome (aHUS) associated with a pathogenic mutation in the factor H gene (C623S). After 15 days of treatment, she suffered a sudden cardiac arrest and died despite intensive resuscitation attempts. She showed only one cardiovascular risk factor, hypercholesterolaemia. Her sudden death was secondary to cardiac infarction related to a coronary thrombotic microangiopathy. This is the first case of aHUS related to a mutation in the factor H gene associated with cardiac microangiopathy. This case emphasizes the need to screen for cardiac complication during the treatment of aHUS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20305136     DOI: 10.1093/ndt/gfq160

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  24 in total

1.  Complement factor B mutation-associated aHUS and myocardial infarction.

Authors:  Natália Noronha; Filipa Dias Costa; Andrea Dias; Alexandra Dinis
Journal:  BMJ Case Rep       Date:  2017-07-14

Review 2.  Cardiovascular complications in atypical haemolytic uraemic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2014-01-14       Impact factor: 28.314

3.  Macrovascular involvement in a child with atypical hemolytic uremic syndrome.

Authors:  Karolis Ažukaitis; Chantal Loirat; Michal Malina; Irina Adomaitienė; Augustina Jankauskienė
Journal:  Pediatr Nephrol       Date:  2013-12-19       Impact factor: 3.714

Review 4.  Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.

Authors:  Julien Zuber; Fadi Fakhouri; Lubka T Roumenina; Chantal Loirat; Véronique Frémeaux-Bacchi
Journal:  Nat Rev Nephrol       Date:  2012-10-02       Impact factor: 28.314

Review 5.  Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations.

Authors:  Maurizio Salvadori; Elisabetta Bertoni
Journal:  World J Nephrol       Date:  2013-08-06

Review 6.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

7.  Rapid conditional targeted ablation model for hemolytic anemia in the rat.

Authors:  Marina M Hanson; Fengming Liu; Shen Dai; Alison Kearns; Xuebin Qin; Elizabeth C Bryda
Journal:  Physiol Genomics       Date:  2016-07-01       Impact factor: 3.107

8.  Recovery of renal function after long-term dialysis and resolution of cardiomyopathy in a patient with aHUS receiving eculizumab.

Authors:  Khadizha Emirova; Elena Volokhina; Evgenia Tolstova; Bert van den Heuvel
Journal:  BMJ Case Rep       Date:  2016-02-15

9.  Extra-Renal manifestations of atypical hemolytic uremic syndrome in children.

Authors:  Kibriya Fidan; Nilüfer Göknar; Bora Gülhan; Engin Melek; Zeynep Y Yıldırım; Esra Baskın; Mutlu Hayran; Kaan Gülleroglu; Zeynep B Özçakar; Fatih Ozaltin; Oguz Soylemezoglu
Journal:  Pediatr Nephrol       Date:  2018-04-02       Impact factor: 3.714

Review 10.  Extra-renal manifestations of atypical hemolytic uremic syndrome.

Authors:  Cassandra Formeck; Agnieszka Swiatecka-Urban
Journal:  Pediatr Nephrol       Date:  2018-08-14       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.